CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
March 2019—Binding Site’s Immunologicals Group has added five recombinant Epstein-Barr virus antigens to its line of products for in vitro diagnostic manufacturing and research applications. The EBV capsid antigen P18; EBV capsid antigen P23; EBV early antigen P138; EBV early antigen P54; and EBV nuclear antigen EBNA1, P72 have been designed for use as components within solid phase enzyme immunoassay test procedures, especially ELISA. The antigens are E. coli source-derived recombinant proteins.
The company has also added purified monoclonal antibodies to be used for the analysis and testing of the hepatitis C virus and include HCV core-2 mAb, HCV core-12 mAb, HCV core-18 mAb, and HCV Ns3 (3.7.4.6) mAb. These monoclonal antibodies have been designed for use as components within enzyme immunoassay test procedures, including ELISA, and are sourced from mice and manufactured to a purity level of greater than 95 percent.